AstraZeneca Trial Results In Focus Amid China Sales Concerns -- Market Talk

Dow Jones

Jan 20, 2025

0802 GMT - AstraZeneca should have a catalyst-rich year with seven late-stage trial results, Berenberg analysts say in a note. However, the company faces headwinds from a lower-performing China business and generics of its type-2 diabetes drug Farxiga, Berenberg says. The British pharma major expects a China sales decline in 4Q and 2025. This is due to its continuing anticorruption investigation of its China employees, but AstraZeneca has strong underlying momentum in the rest of its business, the analysts say. Berenberg forecasts 2025 sales growth of 10%, at constant currencies, and EPS growth of 14%, both lower than the company's guided high teens growth rate for 2024. (helena.smolak@wsj.com)

(END) Dow Jones Newswires

January 20, 2025 03:02 ET (08:02 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2504420005"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2504420005\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2504420005?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-20 16:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2504420005","market":"nz","top_or_hot":-1,"title":"AstraZeneca Trial Results In Focus Amid China Sales Concerns -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0802 GMT - AstraZeneca should have a catalyst-rich year with seven late-stage trial results, Berenberg analysts say in a note. However, the company faces headwinds from a lower-performing China business and generics of its type-2 diabetes drug Farxiga, Berenberg says. The British pharma major expects a China sales decline in 4Q and 2025. This is due to its continuing anticorruption investigation of its China employees, but AstraZeneca has strong underlying momentum in the rest of its business, the analysts say. Berenberg forecasts 2025 sales growth of 10%, at constant currencies, and EPS growth of 14%, both lower than the company's guided high teens growth rate for 2024. (helena.smolak@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 20, 2025 03:02 ET (08:02 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca Trial Results In Focus Amid China Sales Concerns -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca Trial Results In Focus Amid China Sales Concerns -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-01-20 16:02</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0802 GMT - AstraZeneca should have a catalyst-rich year with seven late-stage trial results, Berenberg analysts say in a note. However, the company faces headwinds from a lower-performing China business and generics of its type-2 diabetes drug Farxiga, Berenberg says. The British pharma major expects a China sales decline in 4Q and 2025. This is due to its continuing anticorruption investigation of its China employees, but AstraZeneca has strong underlying momentum in the rest of its business, the analysts say. Berenberg forecasts 2025 sales growth of 10%, at constant currencies, and EPS growth of 14%, both lower than the company's guided high teens growth rate for 2024. (helena.smolak@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 20, 2025 03:02 ET (08:02 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AZN","symbol_name":"阿斯利康","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2504420005","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2504420005","pubTimestamp":1737360120,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0802 GMT - AstraZeneca should have a catalyst-rich year with seven late-stage trial results, Berenberg analysts say in a note. However, the company faces headwinds from a lower-performing China business and generics of its type-2 diabetes drug Farxiga, Berenberg says. The British pharma major expects a China sales decline in 4Q and 2025. This is due to its continuing anticorruption investigation of its China employees, but AstraZeneca has strong underlying momentum in the rest of its business, the analysts say. Berenberg forecasts 2025 sales growth of 10%, at constant currencies, and EPS growth of 14%, both lower than the company's guided high teens growth rate for 2024. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"AZN":"阿斯利康"},"translate_title":"阿斯利康试验结果因中国销售担忧而成为焦点——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":0.9},"content_text":"0802 GMT - AstraZeneca should have a catalyst-rich year with seven late-stage trial results, Berenberg analysts say in a note. However, the company faces headwinds from a lower-performing China business and generics of its type-2 diabetes drug Farxiga, Berenberg says. The British pharma major expects a China sales decline in 4Q and 2025. This is due to its continuing anticorruption investigation of its China employees, but AstraZeneca has strong underlying momentum in the rest of its business, the analysts say. Berenberg forecasts 2025 sales growth of 10%, at constant currencies, and EPS growth of 14%, both lower than the company's guided high teens growth rate for 2024. (helena.smolak@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 20, 2025 03:02 ET (08:02 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}